Arcturus Therapeutics Receives Approval from Health Sciences Authority to Proceed with Phase 2 Study of Vaccine Candidate

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) reported approval from the Singapore Health Sciences Authority to commence its Phase 2 clinical study of its vaccine candidate ARCT-021. The study will utilize its favorable phase ½ study results, including supportive preclinical data. “We are pleased to advance ARCT-021 into a Phase 2 study...

Read Full Story

If the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com

ARCT Arcturus Arcturus Therapeutics Health Sciences Authority Singapore Health Sciences Authority Steve Hughes